# Genmab’s latest phase 2 data spur claim ADC is ‘clearly superior’ to AbbVie’s Elahere

> **Open Intelligence Dossier** · First detected: 2026-10-05 20:40 UTC · Category: Business

## Executive Summary
5 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.

## Intelligence Brief
"Genmab’s latest phase 2 data spur claim ADC is ‘clearly superior’ to AbbVie’s Elahere" is generating significant coverage in the Business category, with 5 articles from 5 distinct sources tracked by PULSE so far.


Outlets currently covering the story include Endpoints News, TradingView, The Pharma Letter and Business Wire. PULSE measures a story's velocity from how quickly new articles appear and how many independent newsrooms join the coverage.


This brief was generated by PULSE's extractive engine from coverage metadata only. The latest headlines from every source are listed below; the velocity chart shows how the story is developing in real time.

## Multi-Source Evidence Table
| Source Outlet | Headline | Verification URL |
|---|---|---|
| European Biotechnology Magazine | Genmab’s Phase 2 data strengthens case for $1.8B ProfoundBio bet | [Source Link](https://news.google.com/rss/articles/CBMirwFBVV95cUxNeF9BeVlEUXBKV0ZrekdhY2l0Tzctc3pIcWF2c0lGdEh3NHI0VlJhV0xKRms5b1VJN1RkMzd0TWREQWVoSzFXbkJqZ2lMb1otZTJBZnNzMmJtWTVHVHBJX2d5V0llZW9OclBjTGZzbDdlTU94RXFVU2dBVjhBbU5oWEhpQzl1bWVUalRya3Eza1ROOUFTTUxpQUFFamozRkhpS1J1QzdhaGFJbFhJTVhj?oc=5) |
| Endpoints News | Genmab details ovarian cancer data; Lilly’s Jaypirca gets a label expansion | [Source Link](https://news.google.com/rss/articles/CBMingFBVV95cUxOQTZZMzlkb1dNZmRlSC1zWU9UVzZJNVozMHYwOFRVSGl3RF9PcU03dDd6bE92VmVYY3B2Wk9UV1dwYklFQm1qSkVIMzNmTFRsT3poN1B3UlJRUUljRHIzc0dRR3RsY2N0MENZd3JVTzlQZm8xTUxlUnNBdllZT081YzMtczZodjhFakhuNVFuaFFwcG85Y0lXMkh3Z3psQQ?oc=5) |
| TradingView | Weekly Recap: Rina‑S 45.9% ORR and Darwin Global 5.11% voting control | [Source Link](https://news.google.com/rss/articles/CBMixwFBVV95cUxPYnNKTTFqOXRER29yMHZCZjNnZE01Njh4dkMzYnIzaVB5T3NQVE5lUHFyZ084VXNEeXF1U01MSkY0MTM1NXNpTmsxSV9sTkZyWkU2QUQ3dU1fN2RlN202ajJEdmt3Y1p1dWlXLWxVR0ZNbnpjSXVmdXhFV3UycDZvSnBUbTRodmVCTGhmMnNwUS1pWl9SSEl0NEZJZHBpRXR5QmM2NXRLaEc1SjNiTnJGWng0TTFmZC1VbklfbWYwbXV0VUxQVVo4?oc=5) |
| The Pharma Letter | Genmab’s Rina-S shows durable responses in ovarian cancer | [Source Link](https://news.google.com/rss/articles/CBMiowFBVV95cUxOQlpLUTJTYWhxQmM5ZXVHTkp2WDhvVlRZTkhPazh6T2J2U2V5MEdGRHZpNEtkMWhQQXQyS3dWbjZ4YWxNRl9LSnc2ZmEwbFJ0TFNXTXRNV1Z1NTdLTU1wbUliSVF6OC1hU2ltVERkTnNabTMtcnNrZENlUk1hMTJ3LUp2RWxZSGN2ZE1BNWc2aW5KdjdHTkduSExvQVcyenBwcWdZ?oc=5) |
| Business Wire | Genmab Announces Rinatabart Sesutecan (Rina-S®) Phase 2 RAINFOL™-01 Results Demonstrated Durable and Clinically Meaningful Responses in Patients with Platinum-Resistant Ovarian Cancer | [Source Link](https://news.google.com/rss/articles/CBMi1wJBVV95cUxOb0RfRzlGOUdMSGY2S1pkXzlXS3ZJRm1fWlJrWDhIUnA4WjQ5Y3VLbm80eEhiRmo4QzZJaW81V3NJWE9nbGZiYm5yUGZUUkdNQ3VQZ3ZFMHU0ZGZKdndlb3g3VThqSHBVb3h0Y2I1MnFMX00yRzhiSW1NZUJHdHVLQUczM21NZlJ2clVVLWxpLW1zUWV1eC03QWRKV2xhMWVZNHlfeTJ3cm9iSmV0MkRJeDduZjMtUG1DYVZ3SFBsUWV5MmZCYlRvRkFGbGcxRWl2VHZjVWxVZGYzck1xY3VDdVJHNGgyTmxyVXlELVNJUFRnd0FzUFc5M2YwMS1Cdlc0S3FNczMwSV9IX3F0RkpCQ0RFTTVoQXZGV19XOUxsNGpsMGdjOThTYi1IcHdZWng3THhhOHQtU3dWNDI5Zl9sSGN2UTFzZWxLUURFZS1PaG5KRy1SbHJ) |
| Fierce Biotech | Genmab’s latest phase 2 data spur claim ADC is ‘clearly superior’ to AbbVie’s Elahere | [Source Link](https://news.google.com/rss/articles/CBMingFBVV95cUxNaVVhNWU5c3BuNjJkdnpGMGEtcUV1ZjNFcG92ZnZCM2R6SE42VDJPSUhpcTVLZmY1UHdBWjBsWktlVUc0ZnZOQzYwNDEzbEFvanZNVFE3SVdFSjZJMVh5SGxiaHViQTYzLWxUWEdiWVJOT2h4eGhnek1fZ1RrV1o2ZXlBdVJ2YzhFejlEaDJhWFVCdml1M2czN1hIYjlzUQ?oc=5) |

---
*Canonical Source: https://pulse.byoviral.com/trend/2026-10-05/genmab-s-latest-phase-2-data-spur-claim-adc-is-clearly-superior-to-abbvie-s*